NASDAQ:MEDP Medpace - MEDP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $181.94 +1.42 (+0.79%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$175.38▼$182.0850-Day Range$174.31▼$239.5252-Week Range$126.94▼$241.48Volume392,472 shsAverage Volume391,015 shsMarket Capitalization$5.65 billionP/E Ratio24.86Dividend YieldN/APrice Target$235.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Medpace MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside29.4% Upside$235.50 Price TargetShort InterestHealthy5.10% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.53Based on 8 Articles This WeekInsider TradingN/AProj. Earnings Growth17.10%From $7.66 to $8.97 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.87 out of 5 starsMedical Sector44th out of 1,005 stocksCommercial Physical Research Industry4th out of 16 stocks 3.0 Analyst's Opinion Consensus RatingMedpace has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $235.50, Medpace has a forecasted upside of 29.4% from its current price of $181.94.Amount of Analyst CoverageMedpace has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.10% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Medpace has recently decreased by 5.47%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedpace has received a 72.85% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Medical devices engineering", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Medpace is -0.62. Previous Next 2.5 News and Social Media Coverage News SentimentMedpace has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Medpace this week, compared to 5 articles on an average week.Search Interest23 people have searched for MEDP on MarketBeat in the last 30 days. This is an increase of 35% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have not sold or bought any company stock.Percentage Held by Insiders20.60% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.49% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Medpace are expected to grow by 17.10% in the coming year, from $7.66 to $8.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 24.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 123.31.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 24.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 123.61.Price to Book Value per Share RatioMedpace has a P/B Ratio of 14.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Medpace (NASDAQ:MEDP) StockMedpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.Read More Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address MEDP Stock News HeadlinesMarch 25, 2023 | americanbankingnews.comMedpace (NASDAQ:MEDP) Lowered to "Hold" at StockNews.comMarch 22, 2023 | finance.yahoo.comMedpace Holdings' (NASDAQ:MEDP) five-year earnings growth trails the 39% YoY shareholder returnsMarch 26, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 21, 2023 | finance.yahoo.comWhat Made Medpace Holdings (MEDP) Stock Outperform in Q4?March 16, 2023 | americanbankingnews.comMedpace (NASDAQ:MEDP) Earns Buy Rating from Analysts at StockNews.comMarch 1, 2023 | finance.yahoo.comMedpace Holdings, Inc. (NASDAQ:MEDP) insider upped their holding by 1.3% earlier this yearFebruary 15, 2023 | finance.yahoo.comMedpace Holdings, Inc. (NASDAQ:MEDP) Q4 2022 Earnings Call TranscriptFebruary 15, 2023 | finance.yahoo.comMedpace Holdings Full Year 2022 Earnings: EPS Beats ExpectationsMarch 26, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.February 13, 2023 | finance.yahoo.comMedpace Holdings, Inc. Reports Fourth Quarter and Full Year 2022 ResultsFebruary 11, 2023 | msn.comMedpace Hldgs's Earnings: A PreviewFebruary 10, 2023 | finance.yahoo.comHere’s Why Investors Hold Medpace Holdings (MEDP)February 6, 2023 | marketwatch.comContract Research Organization (CRO) Services Market 2023 Size Industry, Current Trends, Demand and Size Share Estimation by 2029 with Top PlayersJanuary 23, 2023 | finance.yahoo.comMedpace Holdings, Inc. (MEDP)January 10, 2023 | finance.yahoo.comIBD Stock Of The Day Medpace Flashes Buy Signal — Why You Should Be CautiousJanuary 4, 2023 | finance.yahoo.comMedpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 13, 2023December 28, 2022 | finance.yahoo.comHow Behind-The-Scenes Medpace Navigated A Biotech Slump To Hit A Record HighDecember 23, 2022 | finance.yahoo.comPureval: Medpace's new 1,500-job expansion is ‘truly unprecedented’December 16, 2022 | finance.yahoo.comIBD Stock Of The Day Medpace Shocked Investors — Now It's Eyeing Multiple EntriesDecember 9, 2022 | finance.yahoo.comHere's Why We Think Medpace Holdings (NASDAQ:MEDP) Is Well Worth WatchingNovember 25, 2022 | finance.yahoo.comIs There An Opportunity With Medpace Holdings, Inc.'s (NASDAQ:MEDP) 40% Undervaluation?November 21, 2022 | finance.yahoo.comIs Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"November 11, 2022 | finance.yahoo.comAre Robust Financials Driving The Recent Rally In Medpace Holdings, Inc.'s (NASDAQ:MEDP) Stock?November 1, 2022 | finance.yahoo.comIs Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?October 29, 2022 | finance.yahoo.comWhy Medpace Holdings Jumped 41.5% This WeekOctober 26, 2022 | finance.yahoo.comMedpace (MEDP) is an Incredible Growth Stock: 3 Reasons WhyOctober 25, 2022 | finance.yahoo.comWhy Medpace Stock Soared TodaySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address MEDP Company Calendar Last Earnings2/13/2023Today3/25/2023Next Earnings (Estimated)4/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MEDP CUSIPN/A CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees5,200Year FoundedN/APrice Target and Rating Average Stock Price Forecast$235.50 High Stock Price Forecast$238.00 Low Stock Price Forecast$233.00 Forecasted Upside/Downside+29.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$7.32 Trailing P/E Ratio24.86 Forward P/E Ratio23.75 P/E GrowthN/ANet Income$245.37 million Net Margins16.81% Pretax Margin19.37% Return on Equity60.42% Return on Assets18.38% Debt Debt-to-Equity RatioN/A Current Ratio0.42 Quick Ratio0.42 Sales & Book Value Annual Sales$1.46 billion Price / Sales3.87 Cash Flow$8.74 per share Price / Cash Flow20.82 Book Value$12.42 per share Price / Book14.65Miscellaneous Outstanding Shares31,050,000Free Float24,654,000Market Cap$5.65 billion OptionableOptionable Beta1.42 Key ExecutivesAugust James TroendleChairman & Chief Executive OfficerJesse J. GeigerPresidentSusan E. BurwigExecutive Vice President-OperationsKevin M. BradyChief Financial Officer & TreasurerBrandon EbkenChief Information OfficerKey CompetitorsSyneos HealthNASDAQ:SYNHCharles River Laboratories InternationalNYSE:CRLIncyteNASDAQ:INCYICON PublicNASDAQ:ICLROrganon & Co.NYSE:OGNView All CompetitorsInsiders & InstitutionsB. Riley Wealth Advisors Inc.Bought 2,072 shares on 3/15/2023Ownership: 0.007%Victory Capital Management Inc.Sold 7,440 shares on 3/10/2023Ownership: 0.246%OLD Mission Capital LLCBought 197 shares on 3/6/2023Ownership: 0.001%Rockefeller Capital Management L.P.Bought 112 shares on 3/6/2023Ownership: 0.000%Trust Investment AdvisorsBought 2,528 shares on 2/28/2023Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions MEDP Stock - Frequently Asked Questions Should I buy or sell Medpace stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEDP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEDP, but not buy additional shares or sell existing shares. View MEDP analyst ratings or view top-rated stocks. What is Medpace's stock price forecast for 2023? 3 Wall Street research analysts have issued 1-year price objectives for Medpace's shares. Their MEDP share price forecasts range from $233.00 to $238.00. On average, they predict the company's share price to reach $235.50 in the next year. This suggests a possible upside of 29.4% from the stock's current price. View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts. How have MEDP shares performed in 2023? Medpace's stock was trading at $212.41 on January 1st, 2023. Since then, MEDP stock has decreased by 14.3% and is now trading at $181.94. View the best growth stocks for 2023 here. When is Medpace's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 24th 2023. View our MEDP earnings forecast. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) announced its quarterly earnings results on Monday, February, 13th. The company reported $2.12 EPS for the quarter, beating the consensus estimate of $1.78 by $0.34. The business had revenue of $394.10 million for the quarter, compared to analysts' expectations of $386.09 million. Medpace had a net margin of 16.81% and a trailing twelve-month return on equity of 60.42%. The company's quarterly revenue was up 27.7% on a year-over-year basis. During the same period last year, the firm earned $1.32 EPS. What ETFs hold Medpace's stock? ETFs with the largest weight of Medpace (NASDAQ:MEDP) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), Franklin Genomic Advancements ETF (HELX), AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Argent Mid Cap ETF (AMID), WisdomTree U.S. Growth & Momentum Fund (WGRO), Global X Founder-Run Companies ETF (BOSS) and ROBO Global Healthcare Technology and Innovation ETF (HTEC). What guidance has Medpace issued on next quarter's earnings? Medpace issued an update on its FY 2023 earnings guidance on Tuesday, February, 14th. The company provided EPS guidance of $7.53-$8.14 for the period, compared to the consensus EPS estimate of $7.72. The company issued revenue guidance of $1.69 billion-$1.75 billion, compared to the consensus revenue estimate of $1.70 billion. What is August Troendle's approval rating as Medpace's CEO? 268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG). When did Medpace IPO? (MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers. What is Medpace's stock symbol? Medpace trades on the NASDAQ under the ticker symbol "MEDP." Who are Medpace's major shareholders? Medpace's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Fuller & Thaler Asset Management Inc. (3.02%), Dimensional Fund Advisors LP (1.90%), Geode Capital Management LLC (1.88%), Boston Trust Walden Corp (1.76%), Riverbridge Partners LLC (1.47%) and Millennium Management LLC (1.45%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Medpace's stock price today? One share of MEDP stock can currently be purchased for approximately $181.94. How much money does Medpace make? Medpace (NASDAQ:MEDP) has a market capitalization of $5.65 billion and generates $1.46 billion in revenue each year. The company earns $245.37 million in net income (profit) each year or $7.32 on an earnings per share basis. How many employees does Medpace have? The company employs 5,200 workers across the globe. How can I contact Medpace? Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The official website for the company is www.medpace.com. The company can be reached via phone at (513) 579-9911, via email at investor@medpace.com, or via fax at 513-579-0444. This page (NASDAQ:MEDP) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.